Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Influenza, Human × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 241 Carcinoma, Non-Small-Cell Lung 212 Carcinoma, Renal Cell 130 Neoplasm Metastasis 92 Neoplasms 87 Squamous Cell Carcinoma of Head and Neck 78 Carcinoma, Hepatocellular 75 Colorectal Neoplasms 70 Lung Neoplasms 66 Stomach Neoplasms 53 Pancreatic Neoplasms 49 Carcinoma, Transitional Cell 41 Hodgkin Disease 40 Head and Neck Neoplasms 39 Urinary Bladder Neoplasms 36 Breast Neoplasms 36 Ovarian Neoplasms 34 Triple Negative Breast Neoplasms 31 Small Cell Lung Carcinoma 29 Sarcoma 29 Brain Neoplasms 29 Kidney Neoplasms 28 Prostatic Neoplasms 27 Glioblastoma 27 Recurrence 26 Multiple Myeloma 22 Esophageal Neoplasms 22 Skin Neoplasms 20 Lymphoma 20 Uveal Melanoma 19

Interventions

Influenza Vaccines 14 trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine 2 Vaccines 2 Cyclophosphamide 2 ziprasidone 1 thymoglobulin 1 peginterferon alfa-2a 1 fludarabine 1 baloxavir 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Spironolactone 1 Sevelamer 1 Rocuronium 1 Rituximab 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Oseltamivir 1 Nivolumab 1 Nifedipine 1 Nafcillin 1 Molindone 1 Methylprednisolone 1 Melphalan 1 Lurasidone Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05116917 2024-05-28

INFLUENCE

Herlev Hospital

Phase 2 Terminated

Gastrointestinal

Influenza, Human, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡